Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal

The Senegal pre-exposure prophylaxis (PrEP) Demonstration Project was an open-label cohort study assessing the delivery of daily oral PrEP to HIV-negative female sex workers (FSWs) in four Ministry of Health (MoH)-run clinics in Dakar, Senegal. We assessed uptake, retention in care, and adherence over up to 12 months of follow-up as well as HIV infection rates. Between July and November 2015, 350 individuals were approached and 324 (92.6%) were preliminarily eligible. Uptake was high, with 82.4% of eligible participants choosing to enroll and take PrEP. The mean age of those enrolled was 37.7 years (SD = 8.7), and approximately half had not attended school (41.2%). Among the 267 participants who were prescribed PrEP, 79.9 and 73.4% were retained in PrEP care at 6 and 12 months, respectively. Older age among FSWs was found to be the only significant predictor of lower discontinuation. We did not find significant differences in retention by site, education, condom use, or HIV risk perception. There were no new HIV infections at follow-up. Our results showed evidence of high interest in PrEP and very good PrEP retention rates among FSWs at 12-month follow-up when offered in MoH-run clinics, with older age as the only significant predictor of higher PrEP retention. This highlights the role that these clinics can play in expanding PrEP access nationwide.

[1]  G. Gottlieb,et al.  Trends in Reported Sexual Behavior and Y-Chromosomal DNA Detection Among Female Sex Workers in the Senegal Preexposure Prophylaxis Demonstration Project , 2020, Sexually transmitted diseases.

[2]  M. Prosperi,et al.  Potential Impact of Interventions to Enhance Retention in Care During Real-World HIV Pre-Exposure Prophylaxis Implementation. , 2019, AIDS patient care and STDs.

[3]  E. Vittinghoff,et al.  Racial/Ethnic and HIV risk category disparities in PrEP discontinuation among patients in publicly-funded primary care clinics. , 2019, AIDS.

[4]  T. Chiyaka,et al.  Changes Over Time in HIV Prevalence and Sexual Behaviour Among Young Female Sex-Workers in 14 Sites in Zimbabwe, 2013–2016 , 2019, AIDS and Behavior.

[5]  M. Alary,et al.  Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up. , 2019, Gates open research.

[6]  M. Gagnon,et al.  Early antiretroviral therapy and daily pre‐exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study , 2018, Journal of the International AIDS Society.

[7]  H. Rees,et al.  HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project , 2017, PLoS medicine.

[8]  N. Ford,et al.  Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis , 2017, Journal of acquired immune deficiency syndromes.

[9]  J. Baeten,et al.  Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence , 2017, Journal of the International AIDS Society.

[10]  L. Mofenson,et al.  Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding , 2017, AIDS.

[11]  A. van der Straten,et al.  Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. , 2017, AIDS Research and Human Retroviruses.

[12]  R. Grant,et al.  Effectiveness and safety of oral HIV preexposure prophylaxis for all populations , 2016, AIDS.

[13]  K. Mayer,et al.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). , 2016, AIDS research and human retroviruses.

[14]  J. Baeten,et al.  Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. , 2015, AIDS.

[15]  R. Kaul,et al.  Risk Factors for HIV Acquisition in a Prospective Nairobi-Based Female Sex Worker Cohort , 2015, AIDS and Behavior.

[16]  James Y. Dai,et al.  Tenofovir-based preexposure prophylaxis for HIV infection among African women. , 2015, The New England journal of medicine.

[17]  SarrMoussa,et al.  Effectiveness of the Community PROMISE and Enhanced Community PROMISE Interventions among Female Sex Workers in the Dakar Region, Senegal , 2014 .

[18]  J. Urquhart,et al.  Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials , 2014, Clinical pharmacology and therapeutics.

[19]  J. Baeten,et al.  Preexposure Prophylaxis for HIV Prevention: Where Have We Been and Where Are We Going? , 2013, Journal of acquired immune deficiency syndromes.

[20]  C. Hendrix,et al.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.

[21]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[22]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[23]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[24]  J. Baeten,et al.  Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence , 2012, Current opinion in infectious diseases.

[25]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[26]  S. Mboup,et al.  Concentrated and linked epidemics of both HSV-2 and HIV-1/HIV-2 infections in Senegal: public health impacts of the spread of HIV , 2009, International journal of STD & AIDS.

[27]  N. Kiviat,et al.  HIV prevalence, previous HIV testing, and condom use with clients and regular partners among Senegalese commercial sex workers , 2007, Sexually Transmitted Infections.

[28]  C. Niang,et al.  Low and stable HIV infection rates in Senegal: natural course of the epidemic or evidence for success of prevention? , 1999, AIDS.